Author Archives: James Carroll

About James Carroll

Founder and CEO at THOR Photomedicine Ltd. About THOR

LumiThera LT-300 Device for treating Dry Advanced Macular Degeneration granted CE Mark

LumiThera LT-300 Light Delivery System“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II Clinical Study in select European sites in the upcoming months,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”

“It is very exciting to see the development of PBM treatment for dry AMD patients,” stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto. “These patients have limited options and losing their central vision is horribly debilitating to their quality of life. The previous LIGHTSITE I Clinical Studies demonstrated that PBM therapy was most beneficial in early stage dry AMD patients. It was also determined that retreatments at scheduled intervals will be needed to maintain clinical benefits.”

Read the full press release:
LumiThera LT-300 Device For Treating Dry Advanced Macular … Continue reading

Posted in Industry | 2 Comments

PBM Therapy Literature Watch January 2018

27 Photobiomodulation therapy papers published in January 2018. Highlights include:

  • Treatment 6h before + immediately before exercise best for reducing muscle fatigue
  • Review of pre-clinical data for dementia, Parkinson’s, stroke, trauma and depression
  • Improved bacteriological, cytological and clinical benefits after root planing (RCT)
  • Improved wound healing of skin graft donor site (RCT)
  • Systematic review of RCTs on  LED PBM therapy in dermatology
  • NSAIDs vs PBM Therapy post root canal (RCT)
  • ESWT vs PBM Therapy for Plantar Fasciitis (RCT)
  • Effect of PBM on cerebral hemodynamics and metabolism are not thermal
Posted in Research | Leave a comment

Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

National Institute for Health and Care Excellence (NICE)
RESULT: After three presentations and much correspondence over a 5 year period we have a recommendation guideline from the National Institute of Health and Care Excellence (NICE) — LLLT for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This means the NHS can start using our treatment on cancer patients to reduce some of the painful side effects of cancer treatments.

Read here: https://www.nice.org.uk/guidance/ipg615

Posted in Industry | 1 Comment

LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data

The LT-300 LED ophthalmologic instrument station provides a multi-wavelength approach to treating ocular disease.The LIGHTSITE I data was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern. Dr. Munk was part of the investigator team.

“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05). Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. Munk.

“Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. “The … Continue reading

Posted in Industry | Leave a comment

LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

The LT-300 LED ophthalmologic instrument station provides a multi-wavelength approach to treating ocular disease.LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France.

This is great news for patients suffering from dry AMD who have no other treatment alternatives!

Read the full press release:
LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.

Posted in Industry | 2 Comments

The story of how LLLT / Photobiomodulation was discovered

This is an extraordinary lecture. It is the story of how LLLT / Photobiomodulation was discovered, and because of the context in which it occurred you might also find it very moving, so get some tissues. It is an hour and 10 minutes long so get comfortable, maybe get some popcorn and a drink too. I will paste the email that Andrew Mester wrote into the comments section below.

Here is the email from Andrew Mester :

I had the privilege to give a keynote presentation at the most recent NAALT (North American Association of PhotobiomoduLation Therapy) meeting in February 5, 2017 in Coronado Island, San Diego. The title of paper was: “Invention of Laser Biostimulation”. My lecture is in Youtube now.

BACKGROUND:
Photo-medicine is an exciting new field in both scientific and clinical research all over the world and most recently in the USA. I learned in this interesting meeting that low intensity laser and LED light may stimulate, heal and regenerate neural tissue. … Continue reading

Posted in Conference, Interviews, Special Feature | Leave a comment

LLLT / Photobiomodulation cures acute thrombocytopenia in mice

Zhang et al showed that whole body 810nm laser 100mW/cm2, 30J/cm2 cures acute thrombocytopenia in mice.

Thrombocytopenia is a common hematologic disorder that is managed primarily by platelet transfusions. They showed that noninvasive whole-body illumination cures acute thrombocytopenia triggered by g-irradiation within 2 weeks in mice, as opposed to a 5-week recovery time required in controls.

The low-level laser (LLL) also greatly accelerated platelet regeneration in the presence of anti-CD41 antibody that binds and depletes platelets, and prevented a severe drop in platelet count caused by a common chemo-therapeutic drug.

They conclude: this safe, drug-free, donor-independent modality represents a paradigm shift in the prophylaxis and treatment of thrombocytopenia.

Full abstract and paper here http://stm.sciencemag.org/content/8/349/349ra101

As you know we are investigating the many possible benefits of whole body treatment PBM with our NovoTHOR light pod novoTHOR.com

NovoTHOR: The whole-body light pod using Photobiomodulation Therapy

Posted in Research | Leave a comment